

EDITORIAL

What lower the development of nanodrug?

Chong Qiu

State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; cqiu@icmm.ac.cn

Only a few nanomedicines have entered clinical application after over a decade and billions of dollars of investments in nanoscience and nanotechnology around the world. So, what lower the development of nanodrug? Recently, at our recent Editorial and Editorial Advisory Board meeting, we asked ourselves to address these questions and accelerate the development of nano pharmaceuticals. We will work with leaders in the area of drug supply to share our experiences and compare efforts around the world.

The unique physicochemical, biological, optical, electrical, and catalytic activities of nanodrugs allow them to overcome the pharmacokinetic limitations associated with conventional pharmaceutical agents^[1,2]. An intravenously delivered nanodrug typically has to pass through five consecutive processes^[3]: circulation in the blood compartments, accumulation into the target area, subsequent penetration deeply into the tissue, cellular uptake by cells, and intracellular release of drug from endosome or lysosome. A good nanodrug need to overcome multiple challenges^[4].

Targeting: Numerous studies have shown that most nanodrugs can accumulate up to 0.7% at the target site, which is the biggest obstacle to later inefficiency.

Endosomal/Lysosomal Barrier^[5]: Compared with the physiological pH of 7.4, the pH gradually decreases during maturation of the endosome^[6]. Lysosomes contain various degradative enzymes (such as nucleases and phosphatases), and failure to escape rapidly from lysosomes usually results in entrapment and potential degradation, leading to the unsuccessful delivery of therapeutic drugs^[7,8].

Safety and biocompatibility: As new materials and strategies are developed; it is essential to ensure that they are safe and biocompatible for use in humans. Discuss the importance of evaluating the toxicity and biocompatibility of various nanomaterials and delivery systems.

Scalability and manufacturing: The translation of these strategies to clinical settings will require scalable and cost-effective manufacturing processes. It is important to discuss the challenges related to scaling up the production of nanodrug delivery systems, as well as the need for standardized protocols to ensure reproducibility and quality control^[9].

Regulatory considerations: Address the importance of considering regulatory requirements in the development of nanodrug delivery systems and strategies, particularly as they pertain to safety, efficacy, and quality.

ARTICLE INFO

Received: 16 June 2023 | Accepted: 6 July 2023 | Available online: 21 August 2023

CITATION

Qiu C. What lower the development of Nanodrug? *Micromaterials and Interfaces* 2023; 1(1): 2173. doi: 10.54517/mi.v1i1.2173

COPYRIGHT

Copyright © 2023 by author(s). *Micromaterials and Interfaces* is published by Asia Pacific Academy of Science Pte. Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), permitting distribution and reproduction in any medium, provided the original work is cited.

Interdisciplinary collaboration: An in-depth understanding of nanocarrier trafficking and metabolism may facilitate the rational design of smarter nanodrug delivery systems^[10]. This includes collaborations between researchers from the fields of chemistry, materials science, biology, and medicine, as well as partnerships with industry and regulatory agencies.

Of course, other factors will also affect the process of nanodrug development. We look forward to more people joining the discussion, and we believe that the more arguments there are, the clearer the argument.

Disclosure

Views expressed in this editorial only are derived from author and not necessarily the views of the Micromaterials and Interfaces.

Acknowledgment

We would like to thank our editors, editorial advisory board, and Micromaterials and Interfaces staff for contributing to these and our upcoming discussions.

Conflict of interest

The author declares no conflict of interest.

References

1. Sonksen M, Kerl K, Bunzen H. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. *Medicinal Research Reviews* 2022; 42(1): 374–398. doi: 10.1002/med.21844
2. Tawfik M, Chen F, Goldberg JL, Sabel BA. Nanomedicine and drug delivery to the retina: Current status and implications for gene therapy. *Naunyn-Schmiedeberg's Archives of Pharmacology* 2022; 395: 1477–1507. doi: 10.1007/s00210-022-02287-3
3. Sun Q, Zhou Z, Qiu N, Shen Y. Rational design of cancer nanomedicine: Nanoproperty integration and synchronization. *Advanced Materials* 2017; 29(14). doi: 10.1002/adma.201606628
4. Cheng Z, Li Y, Zhao D, et al. Nanocarriers for intracellular co-delivery of proteins and small-molecule drugs for cancer therapy. *Frontiers in Bioengineering and Biotechnology* 2022; 10: 994655. doi: 10.3389/fbioe.2022.994655
5. Qiu C, Xia F, Zhang J, et al. Advanced strategies for overcoming endosomal/lysosomal barrier in nanodrug delivery. *Research (Washington, D.C.)* 2023; 6: 0148. doi: 10.34133/research.0148
6. Such GK, Yan Y, Johnston AP, et al. Interfacing materials science and biology for drug carrier design. *Advanced Materials* 2015; 27(14): 2278–2297.
7. Lonn P, Kacsinta AD, Cui XS, et al. Enhancing endosomal escape for intracellular delivery of macromolecular biologic therapeutics. *Scientific Reports* 2016; 6: 32301. doi: 10.1038/srep32301
8. Gilleron J, Querbes W, Zeigerer A, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. *Nature Biotechnology* 2013; 31(7): 638–646. doi: 10.1038/nbt.2612
9. Qiu C, Wu Y, Guo Q, et al. Preparation and application of calcium phosphate nanocarriers in drug delivery. *Materials Today Bio* 2022; 17: 100501. doi: 10.1016/j.mtbio.2022.100501
10. Qiu C, Wu Y, Shi Q, et al. Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy. *International Journal of Biological Sciences* 2023; 19(3): 789–810. doi: 10.7150/ijbs.79328